Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

4,050

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

August 5, 2022

Study Completion Date

August 31, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

COVID-19 Protein Subunit Recombinant Vaccine

SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

BIOLOGICAL

Active Comparator

Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus

Trial Locations (4)

Unknown

Faculty of Medicine Diponegoro University, Semarang

Fakultas Kedokteran Universitas Indonesia, Jakarta

Faculty of Medicine Universitas Hassanudin, Makassar

Faculty of Medicine Universitas Andalas, Padang

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Fakultas Kedokteran Universitas Indonesia

OTHER

collaborator

Faculty of Medicine Universitas Diponegoro

UNKNOWN

collaborator

Faculty of Medicine Universitas Andalas

UNKNOWN

collaborator

Faculty of Medicine Universitas Hassanudin

UNKNOWN

lead

PT Bio Farma

INDUSTRY